Login to Your Account

Diamyd Completes Recruitment in Gene Therapy Pain Trial

By Cormac Sheridan
Staff Writer

Wednesday, May 23, 2012

Shares in Diamyd Medical AB edged up more than 6 percent Tuesday on news that the company completed recruitment in a 32-patient, Phase II trial of its gene therapy treatment for chronic cancer pain, NP2 Enkephalin.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription